Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials
Abstract
Background In resected liver-limited metastatic colorectal cancer (LL-mCRC), disease-free survival (DFS) and postsurgical overall survival (psOS) have been found to be weakly related in heterogeneous retrospective series, challenging the role of DFS as a surrogate biomarker of psOS. Additionally, it remains unclear whether early relapses (DFS <6 months) are associated with overall survival (OS) benefit. Patients and methods We analyzed individual data of patients with LL-mCRC enrolled in nine randomized trials of first-line chemotherapy plus biologics. Correlation and surrogacy between DFS and psOS were calculated with ρ and R2. psOS of resected patients with DFS <6 months was compared with time from minimum disease load (post-min OS) of unresected patients, with stratification according to baseline tumor burden score (TBS). Time on systemic therapy was also evaluated. Results Eight hundred fifty-five patients with LL-mCRC were included and 357 (42%) were radically resected. DFS and psOS were highly correlated (ρ = 0.73), with R2 at the patient and trial levels for surrogacy of 0.70 and 0.32, respectively. psOS and post-min OS in resected patients with early relapse (n= 115) and unresected patients (n = 498) were comparable [hazard ratio (HR) 0.88, 95% confidence interval (CI) 0.70-1.11, P = 0.29]. However, a benefit from surgery was detected in patients with high baseline TBS (HR 0.69, 95% CI 0.45-1.05, P = 0.09) but not in patients with low/medium baseline TBS (HR 1.12, 95% CI 0.74-1.69, P = 0.59) (p interaction = 0.10). Resection was associated with a lower percentage of time on systemic therapy (26%) regardless of DFS (47% if <6 months, 26% if ≥6 months) (P < 0.001). Conclusions In LL-mCRC resected after first-line chemotherapy plus biologics, DFS is highly correlated with psOS, with high patient-level surrogacy. In high-burden patients, liver surgery seems associated with a trend toward long-term benefit, also after early relapse (<6 months), whereas time on systemic therapy is reduced.